Q-omics provides the consensus-scored GPR26 profile across patient tissues and cancer cell-line models. GPR26 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPR26 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, GPR26 RNA expression shows 15,160 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BRCA, and GBM as cancer lineages where GPR26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR26 survival associations across molecular data types. GPR26 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR26 RNA expression–survival associations across cancer types. High GPR26 expression shows unfavorable associations in COAD, OV, STAD and MESO, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for GPR26 RNA expression.
This table summarizes GPR26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR26 shows lower tumor expression in READ, COAD, STAD and BLCA and higher tumor expression in BRCA and KICH. The BRCA box plot shows higher GPR26 RNA expression in tumor versus normal tissue (log2 FC = +0.328, t-test p = .001).
This table shows molecular features associated with GPR26 in patient tissues and cancer cell lines. In patient samples, GPR26 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
